Skip to Main Content

Global Blood Therapeutics (GBT) is discontinuing an early-stage program to treat patients with idiopathic pulmonary fibrosis, a progressive and fatal lung disease.

Across two small clinical trials, Global Blood’s lead drug, GBT440, failed to raise oxygen saturation levels high enough in patients to justify moving the idiopathic pulmonary fibrosis (IPF) program forward, the company said Monday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!